Evidence map›Paper›PMID 41155554›Full record

ArticlePharmaceuticals (Basel, Switzerland)2025

Impact of Fixed-Dose Combination Versus Single-Component Therapy for Benign Prostatic Hyperplasia-Related Urinary Symptoms on Persistence, Adherence, and Satisfaction in a Real-Life Setting.

Mateusz Małkowski, Anna Chudek, Agnieszka Almgren-Rachtan, Jerzy Tadeusz Chudek, Piotr Ludwik Chłosta

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mateusz MałkowskiAdamed Pharma S.A., 05-152 Czosnow, Poland.ORCID 0009-0004-4435-4238
Anna ChudekDepartment of Pharmacovigilance, Europharma Research & Science Centre Co., Ltd., 40-061 Katowice, Poland.ORCID 0000-0002-6140-4602
Agnieszka Almgren-RachtanDepartment of Pharmacovigilance, Europharma Research & Science Centre Co., Ltd., 40-061 Katowice, Poland.ORCID 0000-0002-6766-8123
Jerzy Tadeusz ChudekDepartment of Internal Medicine and Oncological Chemotherapy, Medical Faculty in Katowice, Medical University of Silesia, 40-055 Katowice, Poland.ORCID 0000-0002-6367-7794
Piotr Ludwik ChłostaDepartment of Urology, Jagiellonian University Medical College, 31-008 Krakow, Poland.ORCID 0000-0002-5919-4060

Funding

Adamed Pharma S.A. ADM/COMBO/2024
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

adherencebenign prostatic hyperplasiaeveryday clinical practicefixed-dose drugslower urinary tract symptomspersistencereal-life data

Identifiers

PMID41155554
PMCPMC12567054

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.